You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo diseasemucopolysaccharidosis type IIIMPS IIIis a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologicslowing of developmentsevere behavioral problemsprogressive cognitive declinedementiaand decline in motor skills leading to immobilityunresponsivenessand deathWe have focused on MPS IIID caused by a deficiency of a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Molecular Diagnostic Test for Early Onset of Lyme disease

    SBC: Bioscience Development Inc            Topic: NIAID

    Project Summary/Abstract There is no validated assay to reliably detect the early onset of the Lyme disease infection at the time when antibiotic therapy has the best chance of a cure without sequelae. Diagnosis is often difficult because most symptoms are often nebulous, with the telltale “bulls-eye” rash only appearing and clearly recognizable in approximately half of cases. The standard typ ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Painless Defibrillation

    SBC: Coridea, LLC            Topic: NHLBI

    Project SummaryThe purpose of the proposed work is first-in-man testing of novel painless defibrillation (PaDe) therapy. Sudden cardiac arrest (SCA) remains the number one killer in western civilization. The underlying mechanism of SCA is usually ventricular fibrillation (VF), and survival depends on prompt defibrillation. Existing defibrillators rely on the delivery of a brief high voltage shock ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Anti-ceramide scFv as Mitigator of the Radiation GI Syndrome

    SBC: Ceramedix Holding, LLC            Topic: NIAID

    Project Summary/Abstract Inhibition of ceramide protects mice from death from the Radiation GI Syndrome (RGS). Administration of anti- ceramide single-chain Fv (scFv) 24 h post radiation exposure increases survival in intestinal stem cells and dramatically improves overall survival in mice. These data indicate that anti-ceramide scFv represents the first effective mitigator of lethal RGS. To advan ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA

    SBC: Calder Biosciences Inc.            Topic: NIA

    An Influenza pandemic remains an acute threat to world health; and stockpiling a universally protective Influenza vaccine provides a strong defense against this potential catastrophe. The hemagglutinin (HA) protein is the primary target of humoral Ab responses to Influenza; the majority of broadly protective mAbs (bnAbs) against influenza isolated from humans recognize conserved and conformation-s ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

    SBC: Translational Sciences Inc.            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Tau oligomer platform validation using lead series candidate in htau mice

    SBC: Oligomerix, Inc.            Topic: NIA

    TITLETau oligomer platform validation using lead series candidate in htau mice PROJECT SUMMARYSBIR Funding OpportunityAdvancing Research on Alzheimerandapos s DiseaseADand Alzheimerandapos s Disease Related DementiasADRDRRPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand related tauopathiesThere is a critical unmet need for a di ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Validation of a salivary miRNA diagnostic test for autism spectrum disorder

    SBC: Quadrant Biosciences Inc.            Topic: 103

    Autism spectrum disorder (ASD) is a continuum of neurodevelopmental characteristics that includes deficits in communication and social interaction, as well as restrictive, repetitive interests and behaviors. ASD is an increasing public health concern, with about 1 in 45 American children diagnosed with ASD in 2014, a 10-fold increase in prevalence over the past 40 years. The effect of ASD on both ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    ABSTRACT Multiple myeloma (MM) is the second most common hematopoietic cancer and while survival rates have slowly increase in the last 10 years, the five-year survival is just over 50%. The high number of patients that become refractory to current therapies is the core reason for the low long-term survival. Therefore, there is a crucial need to develop unique drugs that are active in refractory a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government